Please upgrade your browser to make full use of twiends.   chrome   firefox   ie   safari  
Want more twitter followers? Find out how.
Sheff
Share this on Twitter “Just stumbled across this cool page for Sheff”
Want to Grow Your Twitter Following, Free?
$AGIO..Leerink states they expect stock-moving data for $AGIO and $EPZM.. investorshub.advfn.com/boards/read_ms…
We'll pay tribute to @jimcramer's father, Ken Cramer, who passed away early this morning .. in a moment. @CNBC
Retweeted by Sheff
$FLML..$13.52..Catalyst Calendar here from now thru 2019. investorshub.advfn.com/boards/read_ms…
The obesity epidemic costs the world $2 trillion a year, says study on.wsj.com/1AkjNOf pic.twitter.com/78zrytsMeW
Retweeted by Sheff
$KBIO..Stifel Presentation Slides from 11/18/14..Upcoming Milestones. bit.ly/1yozuQl investorshub.advfn.com/boards/read_ms…
$TKMR..11/21 Investor Mtng.
$SGYP..$3.08 expecting more pop from this +/ve news. Only up 4%
Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 billion reut.rs/1yo5uUX
Retweeted by Sheff
Reminder - Agios $AGIO - 10am conference call to discuss Phase 1 AG-120 clinical data presented at #ENA2014 investor.agios.com/phoenix.zhtml?…
Retweeted by Sheff
$RCPT: Receptos prices 3.6 mln shares of its common stock at a price to the public of $100.00 per share. Good sense w/ the run its had!
$FOLD: Amicus Therapeutics prices 13,850,000 shares of its common stock at $6.50 per share.
Knight Therapeutics found a buyer for its FDA priority review voucher, selling it to $GILD for $125M. PR: fiercebiotech.com/press-releases…
Retweeted by Sheff
$SGYP Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation. finance.yahoo.com/news/synergy-p…..not gapping.
$OXGN spike to high of $2.09 on massive volume. Pulled back to $2
Roche..FDA approves Avastin (plus chemo) for recurrent, platinun OC. $OXGN in waiting..momo was gone last week!
RT @PropThinker #ASH2014 late-breakers are due on Monday.
MT @Emory_R Public Service Announcement: Today I will be sharing 13F filings I find interesting. Please don't be stupid. Do your own DD//HA!
RT @GantosJ it's hard to see the $IBB in the green while $GILD is dowm ~4% & $CELG 4.75% $BIIB 5.4%.//great pts. as they are bio leaders!
Coming up today on @CNBCClosingBell, tune in for our interview with $ICPT CEO Mark Pruzanksi 3pm ET
Retweeted by Sheff
MT @BioBreakout: $BCRX Trading at support levels w/PDUFA catalyst on December 23 for Peramivir biocryst.com/peramivir pic.twitter.com/2yUIFLRrFO
$IBB down 2.16% or $6.34. Having a Friday enema to cleanse itself for next week:)
Stifel Healthcare Conf Nov 18th-19th. Some solid companies presenting there.
$ZGNX..$1.26 sNDA w/ PDUFA date of late Jan. Low price stock w/ good cash pstn and solid institutional holdings. Baker Bros is an owner.
$KBIO Leerink"The KB-001-A Cystic Fibrosis (CF) study attained full enrollment in July and top-line results are expected in 1Q15, TP=$5..."
Retweeted by Sheff
Dan Gable once said, "Once you've wrestled, everything else in life is easy." Unless, perhaps, you are Willie Burton. es.pn/1qCRMcd
Retweeted by Sheff
$snss WF SNSS: Q3: Qinprezo Data As Late-Breaker At ASH 2014? pic.twitter.com/ohWZAPJmLY
Retweeted by Sheff
twitter $THLD..$3.21 in pre-mkt...Threshold Pharma announced that the FDA granted Fast Track designation for TH-302,
$OXGN..OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab... yhoo.it/1xcV0dZ
Browns sole possession of 1st place for the first time in 19 years.
Retweeted by Sheff
$AEZS canaccord says: "WORSE THAN EXPECTED: COMPLETE RESPONSE FOR MACRILEN RAISES SIGNIFICANT ISSUES - lowering our target to US$0.80($1.45)
Retweeted by Sheff
$AEZS..$.67 post-CRL. This stock should be below $.50. Traders spared here as this hit $.82 a few wks ago b4 we even knew of CRL.
$EXEL Completes Enrllment in Ph.3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma.TopLine Data Q2'15 businesswire.com/news/home/2014…
Retweeted by Sheff
$OXGN..PFS is going to be the key. O/S this wknd is not an important long-term if Avastin gets approved in ovarian cancer w/ PFS.
$CERS..$4.09..on watch for pullback. Should hear soon on announced submission of their protocol to apply Intercept.. investorshub.advfn.com/boards/read_ms…
$SNTA..Synta Announces FDA's Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib. On watch.. investorshub.advfn.com/boards/read_ms…
$RMTI..$8.52..down ahead of ADCOM notes release tomorrow.
$NYMX..$.85 down $4.29. Closed at $5.14 on Friday. Wow!
RT @AnalystWire Summer Street Bullish on Rockwell Medical Technologies $RMTI Into FDA Briefing Docs streetinsider.com/r/9966468
$CPRX..$2.97 ir.catalystpharma.com/events.cfm Presenting data today at 61st Ann Mtng of the Amer Assoc of Neuromuscular and Electrodiagnostic Medicine
$CPRX..$2.92 up 7% today. Pre-NDA mtng w/ FDA on tap in Nov.
$RMTI..$9.20 not participating in today's biotech rally. AdCom notes are out next week. Panel is on Nov 6th.
$CNAT..$7.70 They have a ph 1 late breaking abstract at AASLD.
$CERS..$4.48 patience paid on this one. Was through $4.50 this morning.
$IBB..$301.75 up 1.7%. Lots of green on my screen.